The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients

British Journal of Radiology

Volumn 84, Issue 1003, 2011, Pages 593-599

  Choi, W H ^a   Yoo, Ie Ryung ^a   O, J H ^a   Kim, S H ^a   Chung, S K ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79959580524     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/56324742     Document Type: Article

References (30)

1. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 1993;71:1780-90. (Pubitemid 23067394)
2. Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002;20:4242-8. (Pubitemid 35191027)
3. Markopoulos C, Kouskos E, Gogas H, Mandas D, Kakisis J, Gogas J. Factors affecting axillary lymph node metastases in patients with T1 breast carcinoma.Am Surg 2000;66:1011-13.
4. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000;191:1-6; discussion 6-8.
5. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27 (Suppl 1):S215-29.
6. Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur J Nucl Med Mol Imaging 2004;31 (Suppl 1):S97-102.
7. Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K. Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging 2004;31 (Suppl 1):S125-34.
8. 18F-fluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 2002;71:171-3.
9. van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18] fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002;236:619-24. (Pubitemid 35246894)
10. 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30.
11. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12.
12. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-30. (Pubitemid 29139852)
13. Harris JR, Osteen RT. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat 1985;5:17-21. (Pubitemid 15163213)
14. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival - a Bayesian meta-analysis. Ann Surg Oncol 1999;6:109-16. (Pubitemid 29077496)
15. Scott WJ, Gobar LS, Hauser LG, Sunderland JJ, Dewan NA, Sugimoto JT. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography. Chest 1995;107:1174-6.
16. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998;228:220-7.
17. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose- positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001;93:630-5. (Pubitemid 32409630)
18. Torrenga H, Rahusen FD, Meijer S, Borgstein PJ, van Diest PJ. Sentinel node investigation in breast cancer: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2001;54:550-2. (Pubitemid 32642945)
19. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002;3:73-7. (Pubitemid 34546075)
20. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301-6.
21. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-17.
22. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5.
23. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633-8.
24. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005;26:895-901. (Pubitemid 41426552)
25. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005;46:1819-24. (Pubitemid 46196643)
26. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775-83.
27. Hu Q, Wang W, Zhong X, Yuan S, Fu Z, Guo H, et al. Dualtime- point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol 2009;70:320-4.
28. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen- Auerbach MS, Halpern BS, et al. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7:369-76. (Pubitemid 44193414)
29. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254-62.
30. Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C, et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004;11:846-53.